Michael Keyoung

Dr. Michael Keyoung has over 20 years of experience as a physician, investor, and a healthcare executive.

At CBC Group, Michael serves on the Investment Committee, Management Committee and as Head of Private Credit & Royalty. Michael has led multiple investments in biopharma companies, LBO deals in pharma/medtech companies, and currently serves on the boards of CBC Group’s portfolio companies. He launched the firm’s Private Credit & Royalty strategy in 2020, starting with the R-Bridge Healthcare Fund series, and opened the firm’s U.S. core office in New York City in 2018 as Head of North America.

Prior to joining CBC in 2017, Michael was President and CEO of Genexine Inc., a KOSDAQ listed biotech company developing innovative biologics in immuno-oncology, metabolic and autoimmune diseases. He was also Founding Managing Partner of Portola Capital Partners, a healthcare-dedicated investment firm. He previously served as President of Catalyst Biosciences, a clinical stage NASDAQ-listed biotech company, and as Managing Director and head of Pan-Asia of US venture capital firm Burrill & Company, where he oversaw investments in private and public companies globally. Throughout his career, he has advised leading healthcare companies such as Eli Lilly, Bausch & Lomb, UCB, Samsung Electronics/ Samsung Biologics, and Green Cross (Korea) in global drug development, commercial strategies and partnerships or their regional expansion to Asia.

Michael received both his Medical Doctorate and Ph.D. in Neuroscience and Neurology from Cornell University Weill Medical College and Memorial Sloan Kettering Cancer Center. He was a Howard Hughes Medical Institute Research fellow and received his clinical surgical training at the University of California, San Francisco. He did his biomedical fellowship at the Memorial Sloan Kettering Institute and at Rockefeller University in New York. He also studied Private Equity and Venture Capital at Harvard Business School Executive Education.